Amgen has shared positive results from a late-stage study of its investigational fibroblast growth factor receptor 2b (FGFR2b)-targeted monoclonal antibody bemarituzumab in gastric cancer. The phase 3 FORTITUDE-101 trial, conducted with the support of Zai …
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product base and growing biosimilars segment reduce concentration …
The top-line Phase III findings illustrate potential of the monoclonal antibody plus chemotherapy as a first-line gastric cancer treatment. The first positive top-line results from Amgen’s Phase III FORTITUDE-101 clinical trial in gastric cancer have …
The June 2025 Quorum summarized recent actions by the Federal Trade Commission (“Commission” or “FTC”) and Department of Justice’s Antitrust Division (“DOJ”) indicating the Trump Administration’s rejection of the anti-merger policies of the Biden …
The 15th annual Partnership Opportunities in Drug Delivery (PODD) conference, set for October 27–28, 2025, at the Westin Copley Place in Boston, will spotlight the latest developments in drug delivery technology with a program of expert panels, …
Every page of this book written by investigative journalist Gardiner Harris is packed with shocking information on the functioning of Johnson & Johnson, one of the most respected pharma companies of the world that started out selling bandages and band …
In the phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial (NCT05669599), maridebart cafraglutide (MariTide; Amgen), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently for obesity …
At the close, the Dow Jones Industrial Average was up 0.53% at 44,254.78, while the S&P 500 advanced 0.32% to 6,263.70 and the Nasdaq Composite saw out the session 0.25% firmer at 20,730.49. The Dow closed 231.49 points higher on Wednesday, taking a …
&
